Olumiant

Rheumatoid Arthritis, moderate, active Rheumatoid arthritis, Dermatitis, Atopic + 7 more
Treatment
4 FDA approvals
20 Active Studies for Olumiant

What is Olumiant

BaricitinibThe Generic name of this drug
Treatment SummaryBaricitinib is a medication used to treat moderate to severe rheumatoid arthritis. It works by blocking the action of two proteins, Janus kinase 1 and 2, which are part of an overactive inflammatory pathway. By blocking these proteins, baricitinib reduces inflammation and can help prevent joint damage caused by the condition. It was approved in the EU in 2017 and is marketed as Olumiant. In November 2020, Baricitinib in combination with remdesivir was given emergency approval by the FDA to treat COVID-19.
Olumiantis the brand name
image of different drug pills on a surface
Olumiant Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Olumiant
Baricitinib
2018
3

Approved as Treatment by the FDA

Baricitinib, also known as Olumiant, is approved by the FDA for 4 uses including severe, active Rheumatoid arthritis and Tumor Necrosis Factor Inhibitors .
severe, active Rheumatoid arthritis
Helps manage severe, active Rheumatoid arthritis
Tumor Necrosis Factor Inhibitors
Helps manage Inadequate response or intolerance to TNF blockers
Rheumatoid Arthritis
Helps manage severe, active Rheumatoid arthritis
moderate, active Rheumatoid arthritis
Helps manage moderate, active Rheumatoid arthritis

Effectiveness

How Olumiant Affects PatientsBaricitinib is a medicine used to treat rheumatoid arthritis. In animal studies, it was seen to reduce inflammation, protect joint and bone health, and not have any negative effects on the immune system or blood. Additionally, it has been found to lower the levels of antibodies and a protein (C-reactive protein) in people with rheumatoid arthritis.
How Olumiant works in the bodyJanus kinases (JAKs) are enzymes that activate signals from cytokines and growth factor receptors in the body. They trigger genes that cause inflammation and an autoimmune response. Baricitinib is a medication that works to block JAKs from activating these signals. It stops the inflammatory genes from turning on, and it has also been shown to decrease cell proliferation and trigger cell death in mutated cells.

When to interrupt dosage

The proposed measure of Olumiant is contingent upon the determined condition, such as moderate, active Rheumatoid arthritis, Antirheumatic Agents and Mechanical ventilation. Dosage likewise shifts as per the methodology of application featured in the table below.
Condition
Dosage
Administration
Rheumatoid Arthritis
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Alopecia Areata
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Tumor Necrosis Factor Inhibitors
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Dermatitis, Atopic
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
candidate for systemic therapy
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
moderate, active Rheumatoid arthritis
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Oxyhemoglobin
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Dermatitis, Atopic
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Hospitalizations
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
COVID-19
2.0 mg, , 1.0 mg, 4.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

Olumiant Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Baricitinib may interact with Pulse Frequency
There are 20 known major drug interactions with Olumiant.
Common Olumiant Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Baricitinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Baricitinib is combined with Acteoside.
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Baricitinib.
Begelomab
Major
The risk or severity of adverse effects can be increased when Baricitinib is combined with Begelomab.
Bleselumab
Major
The risk or severity of adverse effects can be increased when Baricitinib is combined with Bleselumab.
Olumiant Toxicity & Overdose RiskTests have shown that the lowest toxic dose of the drug in mice is 1820g/kg and 5096g/kg in rats. Studies have also found that taking doses up to 40mg in a single dose or 20mg daily for 10 days did not cause any significant side effects. After a single dose of 40mg, 90% of the drug is expected to be eliminated from the body within 24 hours. If someone overdoses on the drug, they should be monitored for any signs of adverse reactions, and treated accordingly.
image of a doctor in a lab doing drug, clinical research

Olumiant Novel Uses: Which Conditions Have a Clinical Trial Featuring Olumiant?

74 active trials are now in progress to explore the potential of Olumiant in managing Coronavirus Disease 2019 (COVID‑19), Rheumatoid Arthritis and Hospitalized Patients.
Condition
Clinical Trials
Trial Phases
candidate for systemic therapy
0 Actively Recruiting
Dermatitis, Atopic
0 Actively Recruiting
COVID-19
17 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4
moderate, active Rheumatoid arthritis
0 Actively Recruiting
Dermatitis, Atopic
0 Actively Recruiting
Alopecia Areata
1 Actively Recruiting
Phase 1
Oxyhemoglobin
3 Actively Recruiting
Not Applicable, Phase 1
Rheumatoid Arthritis
0 Actively Recruiting
Hospitalizations
1 Actively Recruiting
Not Applicable
Tumor Necrosis Factor Inhibitors
0 Actively Recruiting

Olumiant Reviews: What are patients saying about Olumiant?

4.3Patient Review
2/21/2022
Olumiant for Rheumatoid Arthritis
I was able to recover from very severe RA symptoms along with heavy bone destruction. Recovery took few months but was stable .
3Patient Review
7/9/2020
Olumiant for Rheumatoid Arthritis
I'm 43 and have had RA since I was 29. I've been on all the meds you can relate to RA, and I'm currently still taking Plaquenil and Sulfasalazine. Three weeks ago, I started Olumiant 4mg . After one week, I started vomiting and got constipated. In week three, I started getting severe upper abdominal pain and ended up in ED with severe Pancreatitis. WILL NEVER TAKE IT AGAIN. If you gets upper abdominal pain while on this medication, go straight to ED.
2.7Patient Review
8/22/2019
Olumiant for Rheumatoid Arthritis
I used this for 11 days and ended up with a whole host of problems: nausea, UTI, sinus infection, and hemorrhoids. So I went off it to take antibiotics and I haven't looked back since.
2.3Patient Review
7/31/2021
Olumiant for Rheumatoid Arthritis
Whenever I would get a very small scratch or poke on my skin it would turn into a hole about the size of a dime. Very sore and I'm still trying to get them healed up. They take months and hurt so bad you can barely touch them. I've been on antibiotics and stopped olumiant. So far I still have the sores after a couple of months.
2Patient Review
12/27/2018
Olumiant for Rheumatoid Arthritis
I've only been on Olumiant for a couple weeks, and the main side effects I've experienced are nausea and vomiting. I haven't eaten anything substantial in days, and all that comes up is water at this point. I was previously on Humira, so it'll be interesting to see if there's a difference in pain levels. I'm also on Methotrexate.
2Patient Review
11/9/2021
Olumiant for Rheumatoid Arthritis
I was extremely disappointed with this medication's ineffectiveness on my RA. Not only that, but I now need a cervical spine fusion because of it. Be very careful of the doctors who push this treatment; my rheumatologist received it for free, then made me pay $1,500 for it. When I complained about the extreme pain in my neck, he refused to change the medication. This caused irreversible damage in multiple locations.
1.7Patient Review
10/24/2021
Olumiant for Rheumatoid Arthritis
This medication was unfortunately very harmful to me, leading to instability in my joints and further damage. I needed surgery as a result of taking this for seven months at a dosage of 4mg per day. My treating physician was unhelpful, continuing the therapy even though he knew it wasn't working and was actually causing harm. Be aware of the potential risks before starting this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about olumiant

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Olumiant approved for alopecia?

"The FDA has approved Olumiant for the treatment of severe alopecia areata. Olumiant is a once-daily pill that is taken orally."

Answered by AI

What kind of drug is Olumiant?

"The drug Baricitinib, also known as Olumiant, is used to treat rheumatoid arthritis by blocking the action of Janus kinase enzymes which are involved in the inflammation that causes the symptoms of rheumatoid arthritis."

Answered by AI

What is Olumiant medication for?

"Olumiant (baricitinib) is a medicine that needs a prescription from a doctor. It is used to treat adults with arthritis that is moderately to severely active. This is after treatment with 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, but did not work well enough or were not tolerated."

Answered by AI

What is Olumiant 4 mg used for?

"There are recessed areas on each side of the tablets. Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs."

Answered by AI

Clinical Trials for Olumiant

Image of AFC Trussville in Trussville, United States.

Metrix Respiratory Panel Test for COVID-19 and Flu

Any Age
All Sexes
Trussville, AL
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix Respiratory Panel Test for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory syncytial virus, and Rhinovirus in anterior nares (AN) swab samples. Additional sites may be added to the study in order to meet minimum subject/sample enrollment requirements and geographic prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus, and Rhinovirus.
Waitlist Available
Has No Placebo
AFC TrussvilleBrad W Killingsworth, M.A.Aptitude Medical Systems
Image of Duke University Health System in Durham, United States.

Pancoronavirus Vaccine for Coronavirus

18 - 55
All Sexes
Durham, NC
Coronaviruses (CoVs) have caused the severe acute respiratory syndrome (SARS) outbreak, the Middle East Respiratory Syndrome (MERS) outbreak, and now the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although there are several approved or authorized vaccines for SARS-CoV-2, there are currently no vaccines approved to prevent diseases caused by multiple different coronaviruses. Two countermeasures with promise for controlling coronavirus outbreaks are recombinant neutralizing antibodies and vaccines directed against the virus. Between these two countermeasures, the ultimate solution to control the current COVID-19 pandemic and future CoV outbreaks is a pancoronavirus vaccine. In particular, a vaccine that can induce broader protection and can prevent severe disease caused by current SARS-CoV-2 variants of concern would help mitigate significant morbidity and mortality following SARS-CoV-2 infection. Additionally, an optimal pancoronavirus vaccine would prevent severe disease from other SARS-related viruses in the genus of coronaviruses-betacoronavirus-that are responsible for past outbreaks or could cause the next major outbreak in humans. Such a broadly active coronavirus vaccine would be an impactful first step towards preventing all life-threatening coronavirus human disease. The proposed vaccine immunogen (Cov-RBD-scNP-001) is composed of an engineered receptor binding domain (RBD) of SARS-CoV-2 WA-1 covalently linked in vitro to the surface of a Helicobacter pylori ferritin protein nanoparticle (RBD-scNP). The RBD has been engineered at two sites to improve its expression. The protein nanoparticle is composed of 24 individual ferritin subunits each of which can have a SARS-CoV-2 WA-1 RBD attached to it via a nine amino acid linker. The protein nanoparticle will be delivered with 3M-052-AF adjuvant - a TLR 7/8 agonist.
Phase 1
Waitlist Available
Duke University Health System
Have you considered Olumiant clinical trials? We made a collection of clinical trials featuring Olumiant, we think they might fit your search criteria.Go to Trials
Image of UCLA Westwood in Los Angeles, United States.

COVID-19 Booster Vaccines for Coronavirus

40 - 64
All Sexes
Los Angeles, CA
The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64. The CoTend-s3BXBB vaccine includes a component called "s3", which was designed to improve the body's response to the vaccine. CoTend-BXBB is the same vaccine without s3. The main questions the study aims to answer are: 1) Is the investigational vaccine safe? 2) Does "s3" lead to bigger, broader, and longer-lasting responses to the vaccine? 5 different doses of the vaccines will be studied. Participants will receive a single dose of either CoTend-s3BXBB, CoTend-BXBB, or placebo. Participants will be monitored for side effects. Saliva, nasal, and blood samples will be collected and immune responses to the vaccine will be measured.
Phase 1 & 2
Recruiting
UCLA Westwood (+1 Sites)Kara Chew, MD, MS
Image of Valley Clinical Trials, Inc. ( Site 3707) in Northridge, United States.

Molnupiravir for COVID-19

18+
All Sexes
Northridge, CA
Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other medicines that may react with a treatment and cause an unwanted effect. Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.
Phase 3
Recruiting
Valley Clinical Trials, Inc. ( Site 3707) (+60 Sites)Medical DirectorMerck Sharp & Dohme LLC
Have you considered Olumiant clinical trials? We made a collection of clinical trials featuring Olumiant, we think they might fit your search criteria.Go to Trials
Have you considered Olumiant clinical trials? We made a collection of clinical trials featuring Olumiant, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security